Empower Pharmacy

• Pharmacy Profile Name: Empower Pharmacy
• Website: empowerpharmacy.com
• Headquarters: 5980 W Sam Houston Pkwy N, Suite 300, Houston, TX 77041
• Pharmacy Type: 503A compounding pharmacy + 503B FDA-registered outsourcing facility
• Accreditations: PCAB accredited; NABP verified
• GLP-1 Compounding: Semaglutide/Cyanocobalamin injection; Tirzepatide/Niacinamide injection; Tirzepatide ODT
• Licensed: All 50 states + Puerto Rico

About the Pharmacy

Empower Pharmacy is one of the largest compounding pharmacies in the United States, operating both 503A and 503B facilities from its Houston, Texas headquarters. It is a pharmacy supplier, not a direct-to-consumer telehealth service — patients cannot order from Empower directly and must access its products through a prescribing provider. During the GLP-1 shortage era, Empower became one of the most widely used backend pharmacies across the telehealth weight loss industry, supplying compounded semaglutide and tirzepatide to a large network of clinics and platforms nationwide.

Its scale is genuinely significant; the product catalog extends well beyond GLP-1s to include hormone therapy, peptides, NAD+ injections, sexual health, dermatology, mental health, and nutritional formulations. That breadth, combined with its 503B outsourcing facility registration, positions Empower as a full pharmaceutical-scale operation. It is also among the most scrutinized compounders in the country, with a regulatory history that predates the GLP-1 boom by nearly a decade.

GLP-1 Compounding

Empower compounds Semaglutide/Cyanocobalamin Injection and Tirzepatide/Niacinamide Injection under strict quality-control protocols. The cyanocobalamin (vitamin B12) addition to semaglutide and the niacinamide (vitamin B3) addition to tirzepatide serve dual purposes: they provide potential metabolic support, and they create formulations that differ from commercially available branded products, a distinction that matters under the “not essentially a copy” regulatory provision compounders use to continue operating post-shortage.

Empower also offers a tirzepatide ODT (orally dissolving tablet), which is the subject of Eli Lilly’s lawsuits against the pharmacy.

Regarding the regulatory environment: while the tirzepatide and semaglutide shortages have resolved, Empower maintains that 503A pharmacies may still compound these drugs if they meet clinical difference criteria under Section 503A of the Federal Food, Drug & Cosmetic Act.

Type of Pharmacy

Empower operates across two facility types:

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

• 503A — patient-specific compounding pharmacy, filling individual prescriptions
• 503B — FDA-registered outsourcing facility, enabling bulk production for distribution to clinics and healthcare providers

Both 503A and 503B facilities are outfitted with advanced equipment that undergoes installation, operational, and performance qualifications. Empower holds PCAB accreditation and NABP verification. However, its regulatory history under both designations is extensive and requires separate treatment.

Regulatory History

Empower’s enforcement record spans nearly a decade across both its 503A and 503B operations:

• 2017 FDA Warning Letter — issued after a 2015 inspection found that Empower produced drug products without valid prescriptions for individually identified patients, and that sterile drug products were prepared under insanitary conditions that put patients at risk
• 2021 FDA Warning Letter — issued to the 503B outsourcing facility after a 2020 inspection found that drug products failed to meet the conditions of Section 503B of the FDCA
• 2024 FDA Form 483 — documented fill weight discrepancies in semaglutide vials, inadequate quality control sampling procedures, and deficiencies in aseptic processing areas
• April 2025 FDA Warning Letter — cited drug products intended or expected to be sterile that were prepared, packed, or held under insanitary conditions; the FDA noted that repeated lapses demonstrate that executive management oversight and control over drug manufacture are inadequate and directed Empower to engage a third-party consultant with sterile drug manufacturing expertise
• State actions — at least a dozen states have brought actions against Empower within the last decade, including a California State Board of Pharmacy disciplinary order
• Eli Lilly lawsuits — Eli Lilly filed two separate lawsuits against Empower: one in April 2025 and another in July 2025, alleging unlawful manufacturing and misleading marketing of tirzepatide products; a former employee also made whistleblower allegations about quality and compliance practices, including alleged use of non-pharmaceutical grade ingredients. These are allegations in litigation and have not been proven in court

States Licensed In

Empower is licensed to ship nationwide, including Puerto Rico, with overnight and 2-day shipping options. Its 503B registration enables bulk production and distribution to clinics and healthcare facilities across the country.

Telehealth Providers They Work With

Empower functions as a backend supplier pharmacy for a wide range of telehealth platforms and medical practices. Confirmed telehealth partners include Mochi Health and Lavender Sky Health. Given its scale, Empower is likely used by additional platforms that do not publicly disclose their pharmacy partners by name. Multiple independent clinics and functional medicine practices also partner directly with Empower for prescription fulfillment, as evidenced by public provider testimonials on clinical practice websites.

Pricing from Reviews

Empower does not publish GLP-1 pricing publicly; patients must request pricing through their prescribing provider or telehealth platform. Based on user reports and third-party reviews, compounded semaglutide through Empower-partnered platforms typically runs in the range of $150–$300/month, depending on dose and platform markup. Pricing is set by the telehealth platform or clinic placing the prescription, not by Empower directly.

Overall Reviews

Empower carries a Trustpilot rating of approximately 2.0 out of 5, with 58% of reviews at 1 star, among the lowest in the compounding pharmacy space. Consumer complaints frequently cite medication effectiveness issues, shipping problems, including products arriving warm without ice packs, poor communication, and billing disputes.

Positive reviews note the affordability and availability of compounded GLP-1s at a time when brand-name access was limited, and some patients report meaningful weight loss results. The gap between positive and negative experiences is wide and consistent, suggesting significant variability in fulfillment and product quality across batches and time periods.